Evidence map›Paper›PMID 39106172›Full record

ArticleNucleic acids research2024

Highly sensitive mapping of in vitro type II topoisomerase DNA cleavage sites with SHAN-seq.

Ian L Morgan, Shannon J McKie, Rachel Kim, Yeonee Seol, Jing Xu, Gabor M Harami, Anthony Maxwell, Keir C Neuman

Abstract read
In one paragraph

Article in Nucleic acids research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Ian L MorganBiochemistry and Biophysics Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-6772-6883
Shannon J McKieBiochemistry and Biophysics Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Rachel KimBiochemistry and Biophysics Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Yeonee SeolBiochemistry and Biophysics Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Jing XuBiochemistry and Biophysics Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Gabor M HaramiBiochemistry and Biophysics Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Anthony MaxwellDepartment of Biological Chemistry, John Innes Centre, Norwich NR4 7UH, UK.ORCID 0000-0002-5756-6430
Keir C NeumanBiochemistry and Biophysics Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-0863-5671

Funding

Single-molecule measurements of DNA topology and topoisomerasesZIAHL001056 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI NEUMAN, KEIR · 2009 to 2025
$22.6M
Testing Direct Effects of Topological and Mechanical Stress on Enhancing Anticancer and Antibacterial Drugs that Target Type II TopoisomerasesFI2GM142536 · NIGMS · U.S. NATIONAL HEART LUNG AND BLOOD INST · PI MORGAN, IAN LEWIS · 2022 to 2022
–
Biotechnology and Biosciences Research Council (UK) Institute Strategic Programme Grant BB/P012523/1Intramural NIH HHS ZIA HL001056NIGMS NIH HHS 1FI2GM142536NIGMS NIH HHS FI2 GM142536NIH HHS 1ZIAHL001056Wellcome TrustWellcome Trust 200928/Z16/ZWellcome Trust Investigator Award 110072/Z/15/Z
6 · The paper itself

Abstract

Type II topoisomerases (topos) are a ubiquitous and essential class of enzymes that form transient enzyme-bound double-stranded breaks on DNA called cleavage complexes. The location and frequency of these cleavage complexes on DNA is important for cellular function, genomic stability and a number of clinically important anticancer and antibacterial drugs, e.g. quinolones. We developed a simple high-accuracy end-sequencing (SHAN-seq) method to sensitively map type II topo cleavage complexes on DNA in vitro. Using SHAN-seq, we detected Escherichia coli gyrase and topoisomerase IV cleavage complexes at hundreds of sites on supercoiled pBR322 DNA, approximately one site every ten bp, with frequencies that varied by two-to-three orders of magnitude. These sites included previously identified sites and 20-50-fold more new sites. We show that the location and frequency of cleavage complexes at these sites are enzyme-specific and vary substantially in the presence of the quinolone, ciprofloxacin, but not with DNA supercoil chirality, i.e. negative versus positive supercoiling. SHAN-seq's exquisite sensitivity provides an unprecedented single-nucleotide resolution view of the distribution of gyrase and topoisomerase IV cleavage complexes on DNA. Moreover, the discovery that these enzymes can cleave DNA at orders of magnitude more sites than the relatively few previously known sites resolves the apparent paradox of how these enzymes resolve topological problems throughout the genome.

Indexed as

DNA CleavageDNA GyraseDNA Topoisomerase IVDNA Topoisomerases, Type IIEscherichia coliCiprofloxacinDNADNA, SuperhelicalHigh-Throughput Nucleotide SequencingSequence Analysis, DNACiprofloxacinDNADNA GyraseDNA, SuperhelicalDNA Topoisomerase IVDNA Topoisomerases, Type II

Identifiers

PMID39106172
PMCPMC11381365

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.